REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/04/2025
Voltar para busca
Dado oficial do USPTO
EPCARG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
EPCARG
ST13
US500000088278778Classe
1, 5, 40, 42
Pedido
88278778
Registro
6026619
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
51
Atualização mais recente
08/04/2025
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42
Data de depósito
28/01/2019
Data de registro
07/04/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/04/2020
Última transação
08/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Bonn, DE
Examinador
MIZELLE HOWARD, DEZMONA
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NEUWAY Pharma GmbH
Representantes
LEIGH ANN LINDQUIST SUGHRUE MION, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiologicalbiochemical and biotechnological products and preparations for industrial and scientific purposessmall moleculesbiologicsnucleic acidsproteinslipidspolysaccharidesenzymesantibodiescellsmicroorganismsprotein-based capsids or particles as well as fragmentsfractions and derivatives thereof
Classe 5
Diagnostic preparations for medical purposes; vaccines; pharmaceutical preparationsadjuvantscarriers for active ingredients and drug delivery systems based on an engineered protein capsule for medical use in humans or animalsimplants comprising active ingredients for the prevention or treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulation; all the aforementioned goods only being either drug delivery agents based on an engineered protein capsule or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned goods for use in connection with the treatment or prevention of hepatitis
Classe 40
Manufacture of pharmaceutical productsmedicinal productsmedicaments from pharmaceutical compositions for third parties; all the aforementioned only in relation to drug delivery agents or systems based on an engineered protein capsule and/or pharmaceutical products or preparations for use with a drug delivery agent or system based on an engineered protein capsule; none of the aforementioned for use in connection with the treatment or prevention of hepatitis
Classe 42
Scientific research and development for third partiesin particular in the fields of medicinepharmacydiagnosticschemistrybiologybiochemistry and biotechnology; scientific research and development with regard to the manufacture of pharmaceutical preparationscarriers for active ingredients and drug delivery systems for use in humans or animalsfor third parties; development of pharmaceutical preparationsmedical products for the prevention and treatment of neurologicalneurodegenerativepsychiatricimmune system relatedmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryurologicalgynecologicalreproductiveoncologicalophthalmicrespiratorygastrointestinalhormonaldermatologicallymphaticinflammatoryinfectioushematologicalrenalgeneticbacterial and viral diseasessexual dysfunction and pain as well as for gene therapyvaccination or immunostimmulationfor third parties
Publicações
Histórico de despachos e eventos da marca no USPTO.
51 publicações encontradas
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/04/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/04/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/04/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/04/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
07/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/01/2020
PUBO
PUBLISHED FOR OPPOSITION
21/01/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/01/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/12/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
17/12/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/12/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
16/12/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/11/2019
GNRT
NON-FINAL ACTION E-MAILED
22/11/2019
CNRT
NON-FINAL ACTION WRITTEN
22/11/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
01/11/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/11/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
01/11/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/10/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
15/10/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/10/2019
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/10/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
17/07/2019
GNSL
LETTER OF SUSPENSION E-MAILED
17/07/2019
CNSL
SUSPENSION LETTER WRITTEN
17/07/2019
DMCC
DATA MODIFICATION COMPLETED
27/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/06/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/06/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/06/2019
GNSL
LETTER OF SUSPENSION E-MAILED
10/06/2019
CNSL
SUSPENSION LETTER WRITTEN
10/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/05/2019
ALIE
ASSIGNED TO LIE
17/05/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/05/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/05/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/04/2019
GNRT
NON-FINAL ACTION E-MAILED
12/04/2019
CNRT
NON-FINAL ACTION WRITTEN
12/04/2019
DOCK
ASSIGNED TO EXAMINER
09/04/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
25/02/2019
ALIE
ASSIGNED TO LIE
21/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/02/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
14/02/2019
NWAP
NEW APPLICATION ENTERED
31/01/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EPCARG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.